• 1. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 2. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 3. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An ion-gating multinanochannel system based on a copper-responsive self-cleaving DNAzyme?
  Yang Chen,Di Zhou,Zheyi Meng,Jin Zhai Chem. Commun., 2016,52, 10020-10023

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides 2-arylbenzofuran flavonoids 2-arylbenzofuran flavonoids
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides 2-arylbenzofuran flavonoids

Recent Advances in the Study of (2S,3R)-Dihydrodehydroconiferyl Alcohol (CAS: 28199-69-1): A Promising Bioactive Compound

(2S,3R)-Dihydrodehydroconiferyl Alcohol (CAS: 28199-69-1) is a naturally occurring lignan derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its diverse biological activities. Recent studies have highlighted its potential as an anti-inflammatory, antioxidant, and neuroprotective agent, making it a promising candidate for therapeutic development. This research briefing synthesizes the latest findings on this compound, focusing on its chemical properties, mechanisms of action, and potential applications in medicine.

One of the key breakthroughs in recent research is the elucidation of the compound's mechanism of action in modulating inflammatory pathways. A 2023 study published in the Journal of Natural Products demonstrated that (2S,3R)-Dihydrodehydroconiferyl Alcohol significantly inhibits the production of pro-inflammatory cytokines such as TNF-α and IL-6 in macrophage cells. The study employed a combination of molecular docking simulations and in vitro assays to identify the compound's interaction with key proteins in the NF-κB signaling pathway, providing a molecular basis for its anti-inflammatory effects.

In addition to its anti-inflammatory properties, recent investigations have explored the compound's potential in neurodegenerative diseases. Research published in Neurochemistry International (2024) revealed that (2S,3R)-Dihydrodehydroconiferyl Alcohol exhibits neuroprotective effects in models of Parkinson's disease by reducing oxidative stress and preventing dopaminergic neuron loss. The study utilized both cell culture and animal models, demonstrating dose-dependent protection against neurotoxicity induced by 6-hydroxydopamine, a commonly used Parkinson's disease model.

The compound's antioxidant capacity has also been a focus of recent research. A 2024 study in Free Radical Biology and Medicine employed advanced spectroscopic techniques to characterize the radical scavenging activity of (2S,3R)-Dihydrodehydroconiferyl Alcohol. The results showed superior antioxidant activity compared to standard antioxidants like vitamin E, particularly in lipid peroxidation systems. This finding suggests potential applications in preventing oxidative stress-related conditions, including cardiovascular diseases and aging.

From a chemical perspective, recent advances in synthetic methodologies have improved access to this compound. A 2023 publication in Organic Letters described an efficient asymmetric synthesis route for (2S,3R)-Dihydrodehydroconiferyl Alcohol with high enantiomeric purity. This development is particularly significant as it addresses previous challenges in obtaining sufficient quantities of the compound for detailed biological studies and potential clinical applications.

Looking forward, several research groups are investigating the pharmacokinetic properties and potential structural modifications of (2S,3R)-Dihydrodehydroconiferyl Alcohol to enhance its bioavailability and therapeutic efficacy. Preliminary results from animal studies suggest reasonable oral bioavailability, though further optimization may be required for clinical translation. The compound's multi-target activity profile presents both opportunities and challenges for drug development, requiring careful consideration of structure-activity relationships.

In conclusion, recent research on (2S,3R)-Dihydrodehydroconiferyl Alcohol (CAS: 28199-69-1) has significantly advanced our understanding of its therapeutic potential. The compound's diverse biological activities, coupled with improved synthetic accessibility, position it as a promising lead compound for the development of novel treatments for inflammatory, neurodegenerative, and oxidative stress-related disorders. Future research directions should focus on detailed mechanistic studies, preclinical evaluation of efficacy and safety, and exploration of potential synergistic effects with existing therapies.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)